| Description | Icosabutate (NST-4016) is an orally active derivative of eicosapentaenoic acid that inhibits hepatic inflammation and fibrosis in NASH, improves cardiovascular risk profiles in statin-treated patients with residual hypertriglyceridemia, lowers triglycerides, and may be useful in studies of liver fibrosis and atherosclerosis. |
| In vivo | 在 6-8 周龄的 ob/ob 雄性小鼠中，Icosabutate（每日通过饮食给予 135 mg/kg;连续给药 5 周）能够改善葡萄糖代谢和胰岛素抵抗[1]。 |
| Synonyms | NST-4016, PRC-4016 |
| molecular weight | 374.56 |
| Molecular formula | C24H38O3 |
| CAS | 1253909-57-7 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility | DMSO: 80 mg/mL (213.58 mM), Sonication is recommended. |
| References | 1. van den Hoek AM, et al. Icosabutate Exerts Beneficial Effects Upon Insulin Sensitivity, Hepatic Inflammation, Lipotoxicity, and Fibrosis in Mice.Hepatol Commun. 2019 Dec 24;4(2):193-207. 2. Kastelein JJ, et al. Icosabutate, a Structurally Engineered Fatty Acid, Improves the Cardiovascular Risk Profile in Statin-Treated Patients with Residual Hypertriglyceridemia.Cardiology. 2016;135(1):3-12. |